University of Wisconsin, Madison
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Wisconsin, Madison sits in the top decile of US sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count).
University of Wisconsin, Madison: 1,039 sponsored US clinical trials, 151 recruiting.
University of Wisconsin, Madison sponsors 1,039 registered US clinical trials on ClinicalTrials.gov, 151 of them currently recruiting, and 712 completed. 98 of these trials are in Phase 3-4 (later-stage) and 251 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 10 trials.
Top-decile sponsor footprint
University of Wisconsin, Madison ranks in the top decile of sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
712 of 824 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,039 total, page 3 of 21
Dementia Care Partner Hospital Assessment Tool
NCT05592366
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
NCT06213454
Differences in Postoperative Symptoms With Four Ureteral Stents
NCT06083051
The STRENGTHEN Study
NCT06267521
Comparison of Microglial Activation in Severe Asthma and Healthy Controls
NCT06299592
Vowel Space Expansion Sensorimotor Adaptation
NCT06233513
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
NCT05912647
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
NCT06199713
18F-FLUC PET/MR in Patients With Brain Mets
NCT06159335
RESISTance Exercise for Depression Trial
NCT06110897
Lopinavir/Ritonavir in PLWH With High-Grade AIN
NCT05334004
US Imaging for the Assessment of LUTS
NCT06323109
Diffusion MRI of the Abdomen
NCT05261633
Fully Automated High-Throughput Quantitative MRI of the Liver
NCT05294471
Moderators and Mediators of Perceptual Learning
NCT05894967
Biomarkers Study in Infants With Prior Neonatal Brain Injury
NCT07413900
Storytelling and Mindfulness for Graduate Student Wellbeing
NCT05826860
PET/CT Characterization of Treatment Resistance
NCT05647564
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
NCT05373017
CandyCollect Strep Throat Testing
NCT05175196
Baby Brain Recovery Study
NCT05013736
Mindfulness and ACL Surgery
NCT05542563
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
NCT04785989
Registry for CADASIL
NCT05567744
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
NCT05677880
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT03936478
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
NCT05109494
Effectiveness of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
NCT05810064
Patient Perspectives of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
NCT05846685
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT04989946
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
NCT04867954
UW Undiagnosed Genetic Diseases Program
NCT04586075
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT04573231
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
NCT04161066
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT04174352
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
NCT04150640
The Tick App: Changing Behaviors With Educational Messaging
NCT06880692
Healthy Little Eyes
NCT05971446
Microglia Activation in Asthma
NCT04307667
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
NCT04020276
The Validity of the Quick Renal MRI in Pediatric Kidney Disease
NCT03959163
CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients
NCT03769298
Mechanisms of Pregnancy Vascular Adaptations
NCT03806283
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT03096418
Interventions for Postoperative Delirium: Biomarker-3
NCT03124303
Electrophysiology of Fetal Arrhythmia
NCT03047161
UWCCC Molecular Tumor Board Registry
NCT03023202
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
NCT02508038
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
NCT02688959
GRoup A StrePtococcus
NCT01558804
What is open in the University of Wisconsin, Madison pipeline
151 recruiting of 1,039 indexed (15% open); 712 completed (69%).
Phase mix: 98 late (III/IV) vs 251 early (I/II) (early-phase heavy).
Top condition: Healthy (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Wisconsin, Madison: open-pipeline peers nationwide
Peers matched on 1,039 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,039 trials (± recruiting share)
- University of Washington · 1,048 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Masonic Cancer Center, University of Minnesota · 14% recruiting · 249 trials
- ModernaTX · 14% recruiting · 90 trials
- United States Naval Medical Center, San Diego · 15% recruiting · 41 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
Related
What to do with this University of Wisconsin, Madison page
1,039 registered trials is a research-attention snapshot, not an endorsement of University of Wisconsin, Madison or any single study.
- 151 of University of Wisconsin, Madison's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition University of Wisconsin, Madison studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Wisconsin, Madison pipeline card: 1,039 registered trials from official public datasets.Report a data error.